Tarlatamab
20200491
Phase 2 small_molecule active
Quick answer
Tarlatamab for Relapsed/Refractory Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen
- Indication
- Relapsed/Refractory Small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active